I’m writing this over the north Atlantic as I return from most of a week of very compelling meetings at a castle in Germany. Nominally, the subject of the discussion was something generally referred to as “open source pharma” (OSP). But more particularly, the meeting was about working towards saving the millions of lives a year that are lost either to so called “neglected diseases,” or because those stricken cannot possibly afford the price of the drugs that could provide a cure. Even though the actual cost of manufacturing the drugs they so desperately need may be only pennies a pill.
My father and my baby sisters did not die because the vaccines for measles or the antiretroviral drugs for HIV were not available. They died, in large part, because life-saving vaccines and medicines were priced beyond our reach.